메뉴 건너뛰기




Volumn 9, Issue 5, 2007, Pages 630-639

Premixed insulin treatment for type 2 diabetes: Analogue or human?

Author keywords

Analogue; Diabetes; Hypoglycaemia; Insulin; Postprandial hyperglycaemia; Premixed human insulin; Premixed insulin analogue

Indexed keywords

BIPHASIC INSULIN; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN SENSITIZING AGENT; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

EID: 34547908482     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00654.x     Document Type: Review
Times cited : (91)

References (68)
  • 1
    • 19944390213 scopus 로고    scopus 로고
    • Pathogenesis of type 2 diabetes mellitus
    • Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005; 36: 197-209.
    • (2005) Arch Med Res , vol.36 , pp. 197-209
    • Leahy, J.L.1
  • 2
    • 0035431520 scopus 로고    scopus 로고
    • Importance of postprandial glucose control
    • Bell DS. Importance of postprandial glucose control. South Med J 2001; 94: 804-809.
    • (2001) South Med J , vol.94 , pp. 804-809
    • Bell, D.S.1
  • 3
    • 0023916553 scopus 로고
    • Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus
    • Polonsky KS, Given BD, Hirsch LJ et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 1231-1239.
    • (1988) N Engl J Med , vol.318 , pp. 1231-1239
    • Polonsky, K.S.1    Given, B.D.2    Hirsch, L.J.3
  • 4
    • 0030596338 scopus 로고    scopus 로고
    • Non-insulin dependent diabetes mellitus - A genetically programmed failure of the beta cell to compensate for insulin resistance
    • Polonsky KS, Sturis J, Bell GI. Non-insulin dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996; 334: 777-783.
    • (1996) N Engl J Med , vol.334 , pp. 777-783
    • Polonsky, K.S.1    Sturis, J.2    Bell, G.I.3
  • 5
    • 0028606422 scopus 로고
    • A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis
    • Coates PA, Ollerton RL, Luzio SD, Ismail I, Owens DR. A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res Clin Pract 1994; 26: 177-187.
    • (1994) Diabetes Res Clin Pract , vol.26 , pp. 177-187
    • Coates, P.A.1    Ollerton, R.L.2    Luzio, S.D.3    Ismail, I.4    Owens, D.R.5
  • 6
    • 0032613269 scopus 로고    scopus 로고
    • Rapid-acting insulin secretagogues: A clinical need?
    • Home PD. Rapid-acting insulin secretagogues: A clinical need? Exp Clin Endocrinol Diabetes 1999; 107(Suppl. 4): S115-119.
    • (1999) Exp Clin Endocrinol Diabetes , vol.107 , Issue.SUPPL. 4
    • Home, P.D.1
  • 7
    • 0037737732 scopus 로고    scopus 로고
    • Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review
    • DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 2003; 289: 2254-2264.
    • (2003) JAMA , vol.289 , pp. 2254-2264
    • DeWitt, D.E.1    Hirsch, I.B.2
  • 8
    • 0005169502 scopus 로고    scopus 로고
    • United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group. United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128: 165-175.
    • (1998) Ann Intern Med , vol.128 , pp. 165-175
  • 9
    • 0031912676 scopus 로고    scopus 로고
    • High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study
    • Balkau B, Shipley M, Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-367.
    • (1998) Diabetes Care , vol.21 , pp. 360-367
    • Balkau, B.1    Shipley, M.2    Jarrett, R.J.3
  • 10
    • 0033592101 scopus 로고    scopus 로고
    • Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
    • DECODE study group, on behalf of the European Diabetes Epidemiology Group
    • DECODE study group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.
    • (1999) Lancet , vol.354 , pp. 617-621
  • 11
    • 0035847591 scopus 로고    scopus 로고
    • Glucose tolerance and cardiovascular mortality
    • DECODE study group, on behalf of the European Diabetes Epidemiology Group
    • DECODE study group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality. Arch Intern Med 2001; 161: 397-404.
    • (2001) Arch Intern Med , vol.161 , pp. 397-404
  • 12
    • 0034641568 scopus 로고    scopus 로고
    • Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
    • Stratton IM, Adler AI, Neil HA et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412.
    • (2000) BMJ , vol.321 , pp. 405-412
    • Stratton, I.M.1    Adler, A.I.2    Neil, H.A.3
  • 13
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
    • (1998) Lancet , vol.352 , pp. 837-853
  • 14
    • 0042166232 scopus 로고    scopus 로고
    • Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c)
    • Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885.
    • (2003) Diabetes Care , vol.26 , pp. 881-885
    • Monnier, L.1    Lapinski, H.2    Colette, C.3
  • 15
    • 0003191727 scopus 로고    scopus 로고
    • Medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management-2002 update
    • American Association of Clinical Endocrinologists
    • American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management-2002 update. Endocr Pract 2002; 8(Suppl. 1): 40-82.
    • (2002) Endocr Pract , vol.8 , Issue.SUPPL. 1 , pp. 40-82
  • 16
    • 0032887833 scopus 로고    scopus 로고
    • A desktop guide to type 2 diabetes mellitus
    • International Diabetes Federation (European Diabetes Policy Group)
    • International Diabetes Federation (European Diabetes Policy Group). A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
    • (1999) Diabet Med , vol.16 , pp. 716-730
  • 17
    • 13044287359 scopus 로고    scopus 로고
    • Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: The possible role of hyperglycemia
    • Ceriello A, Bortolotti N, Motz E et al. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: The possible role of hyperglycemia. Metabolism 1999; 48: 1503-1508.
    • (1999) Metabolism , vol.48 , pp. 1503-1508
    • Ceriello, A.1    Bortolotti, N.2    Motz, E.3
  • 18
    • 1242292299 scopus 로고    scopus 로고
    • The post-prandial state in type 2 diabetes and endothelial dysfunction: Effects of insulin aspart
    • Ceriello A, Cavarape A, Martinelli L et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: Effects of insulin aspart. Diabet Med 2004; 21: 171-175.
    • (2004) Diabet Med , vol.21 , pp. 171-175
    • Ceriello, A.1    Cavarape, A.2    Martinelli, L.3
  • 19
    • 0042093769 scopus 로고    scopus 로고
    • New insights on oxidative stress and diabetic complications may lead to a 'causal' antioxidant therapy
    • Ceriello A. New insights on oxidative stress and diabetic complications may lead to a 'causal' antioxidant therapy. Diabetes Care 2003; 26: 1589-1596.
    • (2003) Diabetes Care , vol.26 , pp. 1589-1596
    • Ceriello, A.1
  • 20
    • 0029957413 scopus 로고    scopus 로고
    • Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up
    • Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583.
    • (1996) Diabetologia , vol.39 , pp. 1577-1583
    • Hanefeld, M.1    Fischer, S.2    Julius, U.3
  • 21
    • 0032983666 scopus 로고    scopus 로고
    • Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group
    • Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 20005-20012.
    • (1999) JAMA , vol.281 , pp. 20005-20012
    • Turner, R.C.1    Cull, C.A.2    Frighi, V.3    Holman, R.R.4
  • 22
    • 0036701596 scopus 로고    scopus 로고
    • Novel insulins: Expanding options in diabetes management
    • Gerich JE. Novel insulins: Expanding options in diabetes management. Am J Med 2002; 113: 308-316.
    • (2002) Am J Med , vol.113 , pp. 308-316
    • Gerich, J.E.1
  • 23
    • 17844377294 scopus 로고    scopus 로고
    • Intensifying insulin therapy in patients with type 2 diabetes mellitus
    • Hirsch IB. Intensifying insulin therapy in patients with type 2 diabetes mellitus. Am J Med 2005; 118 (Suppl. 5A): 21S-26S.
    • (2005) Am J Med , vol.118 , Issue.SUPPL. 5A
    • Hirsch, I.B.1
  • 24
    • 8644242919 scopus 로고    scopus 로고
    • Overcoming obstacles: New management options
    • Heinemann L. Overcoming obstacles: New management options. Eur J Endocrinol 2004; 151 (Suppl. 2): T23-T27.
    • (2004) Eur J Endocrinol , vol.151 , Issue.SUPPL. 2
    • Heinemann, L.1
  • 25
    • 17844406362 scopus 로고    scopus 로고
    • Making the transition from oral to insulin therapy
    • Riddle MC. Making the transition from oral to insulin therapy. Am J Med 2005; 118 (Suppl. 5A): 14S-20S.
    • (2005) Am J Med , vol.118 , Issue.SUPPL. 5A
    • Riddle, M.C.1
  • 26
    • 0025078913 scopus 로고
    • Monomeric insulins and their experimental and clinical implications
    • Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923-954.
    • (1990) Diabetes Care , vol.13 , pp. 923-954
    • Brange, J.1    Owens, D.R.2    Kang, S.3    Volund, A.4
  • 27
  • 28
    • 0030805003 scopus 로고    scopus 로고
    • The new era of biotech insulin analogs
    • Brange J. The new era of biotech insulin analogs. Diabetologia 1997; 40(Suppl. 2): S48-S53.
    • (1997) Diabetologia , vol.40 , Issue.SUPPL. 2
    • Brange, J.1
  • 29
    • 0342657181 scopus 로고    scopus 로고
    • Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
    • Kurtzhals P, Schaffer L, Sorensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
    • (2000) Diabetes , vol.49 , pp. 999-1005
    • Kurtzhals, P.1    Schaffer, L.2    Sorensen, A.3
  • 31
    • 0032969538 scopus 로고    scopus 로고
    • Insulin analogs with improved pharmacokinetic profiles
    • Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 1999; 35: 307-335.
    • (1999) Adv Drug Deliv Rev , vol.35 , pp. 307-335
    • Brange, J.1    Volund, A.2
  • 32
    • 0034968761 scopus 로고    scopus 로고
    • Physiological insulin replacement in type 1 diabetes mellitus
    • Bolli GB. Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2001; 109(Suppl. 2): S317-332.
    • (2001) Exp Clin Endocrinol Diabetes , vol.109 , Issue.SUPPL. 2
    • Bolli, G.B.1
  • 33
    • 0033060426 scopus 로고    scopus 로고
    • Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analog, insulin aspart, in healthy volunteers
    • Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analog, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999; 55: 199-203.
    • (1999) Eur J Clin Pharmacol , vol.55 , pp. 199-203
    • Home, P.D.1    Barriocanal, L.2    Lindholm, A.3
  • 34
    • 0032841674 scopus 로고    scopus 로고
    • Insulin aspart (B28 asp-insulin): A fast-acting analog of human insulin: Absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects
    • Mudaliar SR, Lindberg FA, Joyce M et al. Insulin aspart (B28 asp-insulin): A fast-acting analoA of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999; 22: 1501-1506.
    • (1999) Diabetes Care , vol.22 , pp. 1501-1506
    • Mudaliar, S.R.1    Lindberg, F.A.2    Joyce, M.3
  • 35
    • 0030876297 scopus 로고    scopus 로고
    • Insulin lispro: A new quick-acting insulin analog
    • Gale EA. Insulin lispro: A new quick-acting insulin analog. Expert Opin Investig Drugs 1997; 6: 1247-1256.
    • (1997) Expert Opin Investig Drugs , vol.6 , pp. 1247-1256
    • Gale, E.A.1
  • 36
    • 1542787613 scopus 로고    scopus 로고
    • Comparison of insulin aspart and lispro: Pharmacokinetic and metabolic effects
    • Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. Comparison of insulin aspart and lispro: Pharmacokinetic and metabolic effects. Diabetes Care 2003; 26: 2027-2031.
    • (2003) Diabetes Care , vol.26 , pp. 2027-2031
    • Homko, C.1    Deluzio, A.2    Jimenez, C.3    Kolaczynski, J.W.4    Boden, G.5
  • 37
    • 0036833902 scopus 로고    scopus 로고
    • A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes
    • Plank J, Wutte A, Brunner G et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002; 25: 2053-2057.
    • (2002) Diabetes Care , vol.25 , pp. 2053-2057
    • Plank, J.1    Wutte, A.2    Brunner, G.3
  • 38
    • 0030867217 scopus 로고    scopus 로고
    • Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture
    • Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997; 20: 1612-1614.
    • (1997) Diabetes Care , vol.20 , pp. 1612-1614
    • Weyer, C.1    Heise, T.2    Heinemann, L.3
  • 39
    • 0033848386 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart
    • Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000; 56: 399-403.
    • (2000) Eur J Clin Pharmacol , vol.56 , pp. 399-403
    • Jacobsen, L.V.1    Sogaard, B.2    Riis, A.3
  • 40
    • 0036581025 scopus 로고    scopus 로고
    • Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes
    • Hermansen K, Colombo M, Storgaard H et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25: 883-888.
    • (2002) Diabetes Care , vol.25 , pp. 883-888
    • Hermansen, K.1    Colombo, M.2    Storgaard, H.3
  • 41
    • 0036250511 scopus 로고    scopus 로고
    • Twice-daily biphasic insulin aspart 30 vs biphasic human insulin 30: A double-blind crossover study in adults with type 2 diabetes mellitus
    • McSorley P, Bell P, Jacobsen L et al. Twice-daily biphasic insulin aspart 30 vs biphasic human insulin 30: A double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002; 24: 530-539.
    • (2002) Clin Ther , vol.24 , pp. 530-539
    • McSorley, P.1    Bell, P.2    Jacobsen, L.3
  • 42
    • 0029045224 scopus 로고
    • Do insulin-treated diabetic patients use an injection-meal-interval in daily life?
    • Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med 1995; 12: 449-450.
    • (1995) Diabet Med , vol.12 , pp. 449-450
    • Heinemann, L.1
  • 43
    • 0032918159 scopus 로고    scopus 로고
    • Injection-meal interval: Recommendations of diabetologists and how patients handle it
    • Overmann H, Heinemann L. Injection-meal interval: Recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999; 43: 137-142.
    • (1999) Diabetes Res Clin Pract , vol.43 , pp. 137-142
    • Overmann, H.1    Heinemann, L.2
  • 44
    • 0027008265 scopus 로고
    • Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal
    • Heinemann L, Starke AA, Hohmann A, Berger M. Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Horm Metab Res Suppl 1992; 26: 137-139.
    • (1992) Horm Metab Res Suppl , vol.26 , pp. 137-139
    • Heinemann, L.1    Starke, A.A.2    Hohmann, A.3    Berger, M.4
  • 45
    • 10744233670 scopus 로고    scopus 로고
    • Importance of premeal injection time in insulin therapy: Humalog Mix 75/ 25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits
    • Coscelli C, Iacobellis G, Calderini C et al. Importance of premeal injection time in insulin therapy: Humalog Mix 75/25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. Acta Diabetol 2003; 40: 187-192.
    • (2003) Acta Diabetol , vol.40 , pp. 187-192
    • Coscelli, C.1    Iacobellis, G.2    Calderini, C.3
  • 46
    • 2342652848 scopus 로고    scopus 로고
    • Reduced postprandial glycemic excursion with biphasic insulin Aspart 30 injected immediately before a meal
    • Kapitza C, Rave K, Ostrowski K, Heise T, Heinemann L. Reduced postprandial glycemic excursion with biphasic insulin Aspart 30 injected immediately before a meal. Diabet Med 2004; 21: 500-501.
    • (2004) Diabet Med , vol.21 , pp. 500-501
    • Kapitza, C.1    Rave, K.2    Ostrowski, K.3    Heise, T.4    Heinemann, L.5
  • 47
    • 4444380085 scopus 로고    scopus 로고
    • Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients
    • Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract 2004; 66: 23-29.
    • (2004) Diabetes Res Clin Pract , vol.66 , pp. 23-29
    • Warren, M.L.1    Conway, M.J.2    Klaff, L.J.3    Rosenstock, J.4    Allen, E.5
  • 48
    • 4243900460 scopus 로고    scopus 로고
    • Treatment with premixed insulin aspart 30 in type 1 and type 2 diabetes: A randomized 12-week comparison
    • Home PD, Boehm BO, Bott U, Behrend C, Kamp NM, Lindholm A. Treatment with premixed insulin aspart 30 in type 1 and type 2 diabetes: A randomized 12-week comparison. Diabetes Res Clin Pract 2000; 50 (Suppl. 1): S37.
    • (2000) Diabetes Res Clin Pract , vol.50 , Issue.SUPPL. 1
    • Home, P.D.1    Boehm, B.O.2    Bott, U.3    Behrend, C.4    Kamp, N.M.5    Lindholm, A.6
  • 49
    • 34249108029 scopus 로고    scopus 로고
    • Premixed 70/30 insulin aspart suspension improves insulin therapy related QoL in comparison with premixed 70/30 human insulin
    • Yamada S, Tamada T, Suzuki R, Yajima K, Motohashi Y, Shimada A. Premixed 70/30 insulin aspart suspension improves insulin therapy related QoL in comparison with premixed 70/30 human insulin. Diabetes 2005; 54(Suppl. 1): A119.
    • (2005) Diabetes , vol.54 , Issue.SUPPL. 1
    • Yamada, S.1    Tamada, T.2    Suzuki, R.3    Yajima, K.4    Motohashi, Y.5    Shimada, A.6
  • 50
    • 33746954143 scopus 로고    scopus 로고
    • Decreased rates of major hypoglycaemic events lead to improved long term cost effectiveness of biphasic insulin aspart 30/70 versus biphasic human insulin 30 in type 2 diabetic subjects in Danish, Finnish, German, Norwegian, Spanish, Swedish, and UK Settings
    • DB3
    • Lammert M, Palmer AJ, Roze S, Minshall ME, Valentine WJ. Decreased rates of major hypoglycaemic events lead to improved long term cost effectiveness of biphasic insulin aspart 30/70 versus biphasic human insulin 30 in type 2 diabetic subjects in Danish, Finnish, German, Norwegian, Spanish, Swedish, and UK Settings. Value Health 2004; 7: 649, DB3.
    • (2004) Value Health , vol.7 , pp. 649
    • Lammert, M.1    Palmer, A.J.2    Roze, S.3    Minshall, M.E.4    Valentine, W.J.5
  • 51
    • 0034104347 scopus 로고    scopus 로고
    • Improved postprandial glycemic control with Humalog Mix 75/25/25 after a standard test meal in patients with type 2 diabetes mellitus
    • Malone JK, Woodworth JR, Arora V et al. Improved postprandial glycemic control with Humalog Mix 75/25/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000; 22: 222-230.
    • (2000) Clin Ther , vol.22 , pp. 222-230
    • Malone, J.K.1    Woodworth, J.R.2    Arora, V.3
  • 52
    • 0037307367 scopus 로고    scopus 로고
    • A comparison of insulin lispro Mix 75/25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan
    • Mattoo V, Milicevic Z, Malone JK et al. A comparison of insulin lispro Mix 75/25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract 2003; 59: 137-143.
    • (2003) Diabetes Res Clin Pract , vol.59 , pp. 137-143
    • Mattoo, V.1    Milicevic, Z.2    Malone, J.K.3
  • 53
    • 0032787906 scopus 로고    scopus 로고
    • Improved postprandial glycemic control during treatment with Humalog Mix 75/25, a novel protamine-based insulin lispro formulation
    • the Humalog Mix 75/25 Study Group
    • Roach P, Yue L, Arora V, the Humalog Mix 75/25 Study Group. Improved postprandial glycemic control during treatment with Humalog Mix 75/25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999; 22: 1258-1261.
    • (1999) Diabetes Care , vol.22 , pp. 1258-1261
    • Roach, P.1    Yue, L.2    Arora, V.3
  • 54
    • 0036096925 scopus 로고    scopus 로고
    • Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: A randomized trial in type 1 and type 2 diabetic patients
    • Boehm B, Home P, Behrend C et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: A randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393-399.
    • (2002) Diabet Med , vol.19 , pp. 393-399
    • Boehm, B.1    Home, P.2    Behrend, C.3
  • 55
    • 0037368873 scopus 로고    scopus 로고
    • Humalog Mix 75/25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus
    • Herz M, Arora V, Campaigne BN, Scholtz HE, Potgieter MA, Mollentze W. Humalog Mix 75/25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. S Afr Med J 2003; 93: 219-223.
    • (2003) S Afr Med J , vol.93 , pp. 219-223
    • Herz, M.1    Arora, V.2    Campaigne, B.N.3    Scholtz, H.E.4    Potgieter, M.A.5    Mollentze, W.6
  • 56
    • 25844515162 scopus 로고    scopus 로고
    • A randomized, multicentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes
    • Iwamoto Y. A randomized, multicentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes. Diabetologia 2003; 46 (Suppl. 2): A270.
    • (2003) Diabetologia , vol.46 , Issue.SUPPL. 2
    • Iwamoto, Y.1
  • 57
    • 14644421553 scopus 로고    scopus 로고
    • Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with type 1 diabetes: A randomized double-blinded crossover study
    • Chen J-W, Lauritzen T, Christiansen JJ, Jensen LH, Clausen WHO, Christiansen JS. Pharmacokinetic profiles of biphasic insulin aspart 30/ 70 and 70/30 in patients with type 1 diabetes: A randomized double-blinded crossover study. Diabet Med 2005; 22: 273-277.
    • (2005) Diabet Med , vol.22 , pp. 273-277
    • Chen, J.-W.1    Lauritzen, T.2    Christiansen, J.J.3    Jensen, L.H.4    Clausen, W.H.O.5    Christiansen, J.S.6
  • 58
    • 31344447303 scopus 로고    scopus 로고
    • Efficacy of biphasic insulin aspart 70/30 in patients with T2DM not achieving glycemic targets on OADs with/without basal insulin therapy
    • Jain R, Allen E, Wahl T et al. Efficacy of biphasic insulin aspart 70/30 in patients with T2DM not achieving glycemic targets on OADs with/ without basal insulin therapy. Diabetes 2005; 54(Suppl. 1): A69.
    • (2005) Diabetes , vol.54 , Issue.SUPPL. 1
    • Jain, R.1    Allen, E.2    Wahl, T.3
  • 59
    • 34547881925 scopus 로고    scopus 로고
    • Biphasic insulin aspart 30 (NovoLog Mix 70/30), a premier analog, is an effective and well tolerated starter insulin in type 2 diabetes
    • Ushakova O, Sokolovskaya V, Morozova A et al. Biphasic insulin aspart 30 (NovoLog Mix 70/30), a premier analog, is an effective and well tolerated starter insulin in type 2 diabetes. Diabetes 2005; 54 (Suppl. 1): A502.
    • (2005) Diabetes , vol.54 , Issue.SUPPL. 1
    • Ushakova, O.1    Sokolovskaya, V.2    Morozova, A.3
  • 60
    • 0034005755 scopus 로고    scopus 로고
    • The post-prandial state and cardiovascular disease: Relevance to diabetes mellitus
    • Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000; 16: 125-132.
    • (2000) Diabetes Metab Res Rev , vol.16 , pp. 125-132
    • Ceriello, A.1
  • 61
    • 0024333622 scopus 로고
    • Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study
    • Fontbonne A, Eschwege E, Cambien F et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300-304.
    • (1989) Diabetologia , vol.32 , pp. 300-304
    • Fontbonne, A.1    Eschwege, E.2    Cambien, F.3
  • 62
    • 17144406856 scopus 로고    scopus 로고
    • Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with type 2 diabetes
    • Schmoelzer I, de Campo A, Pressl H et al. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2005; 13: 176-181.
    • (2005) Exp Clin Endocrinol Diabetes , vol.13 , pp. 176-181
    • Schmoelzer, I.1    de Campo, A.2    Pressl, H.3
  • 63
    • 12844276715 scopus 로고    scopus 로고
    • Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes
    • Boehm BO, Vaz JA, Brønstedt L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004; 15: 496-502.
    • (2004) Eur J Intern Med , vol.15 , pp. 496-502
    • Boehm, B.O.1    Vaz, J.A.2    Brønstedt, L.3    Home, P.D.4
  • 64
    • 25844443342 scopus 로고    scopus 로고
    • Patients with type 2 diabetes mellitus have lower rates of nocturnal hypoglycemia on biphasic insulin aspart (BIAsp 30) than on biphasic human insulin-30 (BHI30): Data from the REACH study
    • McNally P, Fitch M, Nelson G. Patients with type 2 diabetes mellitus have lower rates of nocturnal hypoglycemia on biphasic insulin aspart (BIAsp 30) than on biphasic human insulin-30 (BHI30): Data from the REACH study. Diabetologia 2004; 47(Suppl. 1): A327.
    • (2004) Diabetologia , vol.47 , Issue.SUPPL. 1
    • McNally, P.1    Fitch, M.2    Nelson, G.3
  • 65
    • 12844265257 scopus 로고    scopus 로고
    • Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs
    • Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265.
    • (2005) Diabetes Care , vol.28 , pp. 260-265
    • Raskin, P.1    Allen, E.2    Hollander, P.3
  • 66
    • 18744383343 scopus 로고    scopus 로고
    • Can continuous glucose monitoring provide objective documentation of hypoglycemia unawareness?
    • Streja D. Can continuous glucose monitoring provide objective documentation of hypoglycemia unawareness? Endocr Pract 2005; 11: 83-90.
    • (2005) Endocr Pract , vol.11 , pp. 83-90
    • Streja, D.1
  • 67
    • 0036580827 scopus 로고    scopus 로고
    • Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes
    • Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002; 25: 876-882.
    • (2002) Diabetes Care , vol.25 , pp. 876-882
    • Lindholm, A.1    Jensen, L.B.2    Home, P.D.3    Raskin, P.4    Boehm, B.O.5    Rastam, J.6
  • 68
    • 85073764666 scopus 로고    scopus 로고
    • Antibody formation, insulin dose and efficacy in a 4-year comparison of twice daily treatment with biphasic insulin aspart 30 or biphasic human insulin 30
    • Home P, Boehm BO, Raastam J, Keiding J. Antibody formation, insulin dose and efficacy in a 4-year comparison of twice daily treatment with biphasic insulin aspart 30 or biphasic human insulin 30. Diabetes 2004; 53(Suppl. 2): A310.
    • (2004) Diabetes , vol.53 , Issue.SUPPL. 2
    • Home, P.1    Boehm, B.O.2    Raastam, J.3    Keiding, J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.